Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Despite mounting evidence supporting the cardio-kidney benefits of sodium/glucose cotransporter 2 inhibitors (SGLT2i), significant disparities in their use exist among people with type 2 diabetes (T2D), cardiovascular, or kidney disease that reveals a significant disconnect between guidelines and practice. These discrepancies are particularly pronounced among women, minority races, and lower socioeconomic groups. These groups remain underrepresented in major cardiovascular trials, potentially leading to their exclusion from optimal therapies and increasing morbidity and mortality rates. This review aims to highlight disparities in the use of SGLT2i in populations with T2D, chronic kidney disease, heart failure, and atherosclerotic cardiovascular disease. It examines the factors that influence the prescription of SGLT2i within these populations and evaluates their downstream impact on clinical outcomes. Finally, the review summarizes recent clinical trial findings on strategies that enhance the adoption of SGLT2i and other cardioprotective agents through a multifaceted approach, aiming to improve real-world adoption for patients with T2D and/or cardiovascular and kidney diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Community health workers and patient navigators play a critical role in bridging healthcare systems with underserved communities by providing tailored education, assisting with appointment scheduling, and connecting patients to insurance and medication-assistance programs [27].”
From Unequal Access to Evidence-Based Cardiometabolic Therapies: Racial Disparities in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use Among Patients With Type 2 Diabetes and Cardiovascular Disease (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Notably, race and ethnicity explained about 26% of the variation, highlighting the ongoing impact of structural and financial inequities [27].”
The cited source says what the claim attributes to it.
In the citing paper
“However, financial barriers remain a major obstacle. Medication costs, out-of-pocket expenses, and insurance type continue to influence access to SGLT2 inhibitors and GLP-1 receptor agonists [27].”
The cited source says what the claim attributes to it.
In the citing paper
“In a study of over 3,000 adults with type 2 diabetes from the 2017-2018 Medical Expenditure Panel Survey, Medicare beneficiaries were less likely to receive these therapies compared with those with private insurance (OR 0.60; 95% CI, 0.36-0.99).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Structural racism and health inequities in the USA: evidence and interventions
Bailey, Z. D., Krieger, N., Agénor, M., Graves, J., Linos, N., & Bassett, M. T. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30569-x · Cited by 5,203
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Sotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Social determinants of health and diabetes: A scientific review
Hill-Briggs, F., Adler, N. E., Berkowitz, S. A., Chin, M. H., Gary-Webb, T. L., Navas-Acien, A., Thornton, P. L., & Haire-Joshu, D. (2021) · Diabetes Care · doi:10.2337/dci20-0053 · Cited by 1,732
Physicians and Implicit Bias: How Doctors May Unwittingly Perpetuate Health Care Disparities
Chapman, E. N., Kaatz, A., & Carnes, M. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2441-1 · Cited by 1,300
Carnethon, M. R., Pu, J., Howard, G., Albert, M. A., Anderson, C. A. M., Bertoni, A. G., Mujahid, M. S., Palaniappan, L., Taylor, H. A., Willis, M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000534 · Cited by 1,147
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 566
Kittleson, M. M., Panjrath, G. S., Amancherla, K., Davis, L. L., Deswal, A., Dixon, D. L., Januzzi, J. L., & Yancy, C. W. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.393 · Cited by 554
Carnes, M., Devine, P. G., Baier Manwell, L., Byars-Winston, A., Fine, E., Ford, C. E., Forscher, P., Isaac, C., Kaatz, A., Magua, W., et al. (2015) · Academic Medicine · doi:10.1097/acm.0000000000000552 · Cited by 499
Javed, Z., Haisum Maqsood, M., Yahya, T., Amin, Z., Acquah, I., Valero-Elizondo, J., Andrieni, J., Dubey, P., Jackson, R. K., Daffin, M. A., et al. (2022) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.007917 · Cited by 491
How Socioeconomic Status Affects Patient Perceptions of Health Care: A Qualitative Study.
Arpey, N. C., Gaglioti, A. H., & Rosenbaum, M. E. (2017) · Journal of Primary Care & Community Health · doi:10.1177/2150131917697439 · Cited by 413
Eberly, L. A., Yang, L., Eneanya, N. D., Essien, U., Julien, H., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., Giri, J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6139 · Cited by 350
Tsapas, A., Avgerinos, I., Karagiannis, T., Malandris, K., Manolopoulos, A., Andreadis, P., Liakos, A., Matthews, D. R., & Bekiari, E. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0864 · Cited by 346
Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure
James, S., Erlinge, D., Storey, R. F., McGuire, D. K., de Belder, M., Eriksson, N., Andersen, K., Austin, D., Arefalk, G., Carrick, D., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2300286 · Cited by 305
Implicit bias in healthcare: clinical practice, research and decision making
Gopal, D. P., Chetty, U., O'Donnell, P., Gajria, C., & Blackadder-Weinstein, J. (2021) · Future Healthcare Journal · doi:10.7861/fhj.2020-0233 · Cited by 298
Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2904 · Cited by 248
Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum
Stolfo, D., Uijl, A., Vedin, O., Strömberg, A., Faxén, U. L., Rosano, G. M. C., Sinagra, G., Dahlström, U., & Savarese, G. (2019) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.03.011 · Cited by 219
Negarandeh, R., Mahmoodi, H., Noktehdan, H., Heshmat, R., & Shakibazadeh, E. (2013) · Primary Care Diabetes · doi:10.1016/j.pcd.2012.11.001 · Cited by 215
A Policy Prescription for Reducing Health Disparities—Achieving Pharmacoequity
Essien, U. R., Dusetzina, S. B., & Gellad, W. F. (2021) · JAMA · doi:10.1001/jama.2021.17764 · Cited by 183
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus
Bays, H. E., Weinstein, R., Law, G., & Canovatchel, W. (2014) · Obesity · doi:10.1002/oby.20663 · Cited by 166
Schernthaner, G., Shehadeh, N., Ametov, A. S., Bazarova, A. V., Ebrahimi, F., Fasching, P., Janež, A., Kempler, P., Konrāde, I., Lalić, N. M., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01154-w · Cited by 164
Panza, G. A., Puhl, R. M., Taylor, B. A., Zaleski, A. L., Livingston, J., & Pescatello, L. S. (2019) · PLOS ONE · doi:10.1371/journal.pone.0217623 · Cited by 163
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2409183 · Cited by 156
Odutayo, A., Gill, P., Shepherd, S., Akingbade, A., Hopewell, S., Tennankore, K., Hunn, B. H., & Emdin, C. A. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1658 · Cited by 155
Mahtta, D., Ramsey, D. J., Lee, M. T., Chen, L., Al Rifai, M., Akeroyd, J. M., Vaughan, E. M., Matheny, M. E., Santo, K. R. D. E., Navaneethan, S. D., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1815 · Cited by 137
Lamprea-Montealegre, J. A., Madden, E., Tummalapalli, S. L., Peralta, C., Neilands, T. B., Garcia, P. K., Muiru, A., Karliner, L., Shlipak, M. G., & Estrella, M. M. (2022) · JAMA · doi:10.1001/jama.2022.13885 · Cited by 129
Obreli-Neto, P. R., Guidoni, C. M., Baldoni, A. O., Pilger, D. A., Cruciol-Souza, J. M., Gaeti, W. P., & Cuman, R. K. N. (2011) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-011-9518-x · Cited by 108
Pagidipati, N. J., Nelson, A. J., Kaltenbach, L. A., Leyva, M., McGuire, D. K., Pop-Busui, R., Cavender, M. A., Aroda, V. R., Magwire, M. L., Richardson, C. R., et al. (2023) · JAMA · doi:10.1001/jama.2023.2854 · Cited by 105
Powell, R. E., Zaccardi, F., Beebe, C., Chen, X. M., Crawford, A., Cuddeback, J., Gabbay, R. A., Kissela, L., Litchman, M. L., Mehta, R., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14455 · Cited by 99
Casting a Health Equity Lens on Endocrinology and Diabetes
Golden, S. H., Joseph, J. J., & Hill-Briggs, F. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa938 · Cited by 93
Jadoul, M. Y., Awan, A. A., Berenguer, M., Bruchfeld, A. N., Fabrizi, F., Goldberg, D. S., Jia, J., Kamar, N., Mohamed, R., Pessôa, M. G., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.07.013 · Cited by 80
Engelhardt, K., Ferguson, M. C., & Rosselli, J. L. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020951928 · Cited by 78
Rivera, F. B., Tang, V. A. S., Luna, D. V. D., Lerma, E. V., Vijayaraghavan, K., Kazory, A., Shah, N. S., & Volgman, A. S. (2023) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2023.100261 · Cited by 64
Wang, X., Vaduganathan, M., Claggett, B. L., Hegde, S. M., Pabón, M. A., Kulac, I. J., Vardeny, O., O’Meara, E., Zieroth, S. R., Katova, T., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.062832 · Cited by 63
Gender differences in adverse event reports associated with antidiabetic drugs
Joung, K.-I., Jung, G.-W., Park, H.-H., Lee, H., Park, S.-H., & Shin, J.-Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-74000-4 · Cited by 61
Kelli, H. M., Mehta, A., Tahhan, A. S., Liu, C., Kim, J. H., Dong, T. A., Dhindsa, D. S., Ghazzal, B., Choudhary, M. K., Sandesara, P. B., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013165 · Cited by 61
Sex-related differences in chronic heart failure
Aimo, A., Vergaro, G., Barison, A., Maffei, S., Borrelli, C., Morrone, D., Cameli, M., Palazzuoli, A., Ambrosio, G., Coiro, S., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.068 · Cited by 52
Community-Based Diabetes Community Health Worker Intervention in an Underserved Chicago Population
Hughes, M. M., Yang, E., Ramanathan, D., & Benjamins, M. R. (2016) · Journal of Community Health · doi:10.1007/s10900-016-0212-8 · Cited by 50
MAP study: RCT of a medication adherence program for patients with type 2 diabetes
Odegard, P. S., & Christensen, D. B. (2012) · Journal of the American Pharmacists Association · doi:10.1331/japha.2012.11001 · Cited by 48
Kunutsor, S. K., Zaccardi, F., Balasubramanian, V. G., Gillies, C., Aroda, V. R., Seidu, S., Davies, M. J., & Khunti, K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15500 · Cited by 48
Gender, socioeconomic and ethnic/racial disparities in cardiovascular disease: A time for change
Ski, C. F., King‐Shier, K. M., & Thompson, D. R. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.10.082 · Cited by 46
Thomas, M., Magwire, M., Gosch, K., Sammour, Y., Mehta, R., O’Keefe, J., Nassif, M. E., & Kosiborod, M. (2021) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007682 · Cited by 46
Gregg, L. P., Ramsey, D. J., Akeroyd, J. M., Jafry, S. A., Matheny, M. E., Virani, S. S., & Navaneethan, S. D. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.11.017 · Cited by 46
Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes
Edmonston, D. L., Lydon, E. J., Mulder, H. S., Chiswell, K., Lampron, Z. M., Marsolo, K. A., Goss, A., Ayoub, I. M., Shah, R. C., Chang, A. R., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.18808 · Cited by 46
Spertus, J. A., Birmingham, M. C., Butler, J., Lingvay, I., Lanfear, D. E., Abbate, A., Kosiborod, M., Fawcett, C., Burton, P. B. J., Damaraju, C. V., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007767 · Cited by 38
Funck, K. L., Bjerg, L., Isaksen, A. A., Sandbæk, A., & Grove, E. L. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01713-3 · Cited by 36
Blood, A. J., Chang, L., Hassan, S., Chasse, J., Stern, G. M., Gabovitch, D., Zelle, D., Colling, C., Aronson, S., Figueroa, C., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069494 · Cited by 35
Devine, A. E., Ignacio, R., Prenter, K., Temminghoff, L., Gill‐Atkinson, L., Zayas, J., Marco, M. J., & Vaughan, C. (2017) · Reproductive Health Matters · doi:10.1080/09688080.2017.1319732 · Cited by 35
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
O’Donoghue, M. L., Kato, E. T., Mosenzon, O., Murphy, S. A., Cahn, A., Herrera, M., Tankova, T. I., Šmahelová, A., Merlini, P. A., Gause‐Nilsson, I. A. M., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05399-2 · Cited by 34
Li, S., Yin, Z., Lesser, J., Li, C., Choi, B. Y., Parra-Medina, D. M., Flores, B., Dennis, B., & Wang, J. (2022) · JMIR Diabetes · doi:10.2196/37534 · Cited by 28
Wang, N., Evans, J., Sawant, S., Sindone, J., & Lal, S. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10275-1 · Cited by 27
Liu, Y., An, C., Liu, P., Yang, F., & Zhao, Q. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2217287 · Cited by 27
Neeland, I. J., Al-Kindi, S. G., Tashtish, N., Eaton, E., Friswold, J., Rahmani, S., Solaru, K. W., Rashid, I., Berg, D., Rana, M. N., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.120.024482 · Cited by 23
Morris, A. A., Testani, J. M., & Butler, J. (2021) · Circulation · doi:10.1161/circulationaha.120.052821 · Cited by 22
Walker, A. F., Addala, A., Sheehan, E., Lal, R., Haller, M., Cuttriss, N., Filipp, S., Baer, L., Gurka, M., Bernier, A., et al. (2022) · Diabetes Spectrum · doi:10.2337/dsi22-0004 · Cited by 21
Beltrán, S., Lett, E., & Cronholm, P. F. (2019) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2019.06.005 · Cited by 21
Gregg, L. P., Richardson, P. A., Nambi, V., Petersen, L. A., Matheny, M. E., Virani, S. S., & Navaneethan, S. D. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000477 · Cited by 19
Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women
Pruett, J. E., Lirette, S. T., Romero, D. G., & Cardozo, L. L. Y. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac191 · Cited by 18
Zhang, Y., Luo, J., Li, B., Xu, J., Yu, H., & Chen, N. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03833-2 · Cited by 18
Wang, E., Patorno, E., Khosrow-Khavar, F., Crystal, S., & Dave, C. V. (2025) · Diabetologia · doi:10.1007/s00125-024-06321-2 · Cited by 14
Limonte, C. P., Lamprea-Montealegre, J. A., & Tuttle, K. R. (2024) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2024.151520 · Cited by 14
Black Race Coefficient in GFR Estimation and Diabetes Medications in CKD: National Estimates
Walther, C. P., Winkelmayer, W. C., & Navaneethan, S. D. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020121724 · Cited by 13
Shao, H., Li, P., Guo, J., Fonseca, V., Shi, L., & Zhang, P. (2022) · Diabetes Care · doi:10.2337/dc21-1800 · Cited by 13
Implicit or Unconscious Bias in Diabetes Care
Caballero, A. E., ElSayed, N. A., Golden, S. H., Bannuru, R. R., & Gregg, B. E. (2023) · Clinical Diabetes · doi:10.2337/cd23-0048 · Cited by 12
Experiences of midlife and older African American men living with type 2 diabetes
Walker, A. Q., Blake, C. E., Moore, J. B., Wilcox, S., DuBois, K., & Watkins, K. W. (2021) · Ethnicity and Health · doi:10.1080/13557858.2021.1910206 · Cited by 11
Gregg, L. P., Worsley, M. L., Ramsey, D. J., Segar, M. W., Matheny, M. E., Virani, S. S., & Navaneethan, S. D. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000266 · Cited by 8
Rikin, S., Bauman, L. J., Arnaoudova, I., Palo, K. E. D., Suda, N., Gupta, S., Deng, Y., & Golestaneh, L. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004155 · Cited by 8
Rangaswami, J., Lo, K. B., Vaduganathan, M., & Mathew, R. O. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.025 · Cited by 7
Shah, A. J., Vorla, M., Jafri, S. H., & Kalra, D. K. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.10.320 · Cited by 6
Shetty, N. S., Parcha, V., Patel, N., Pampana, A., Kalra, R., Pandey, A., Li, P., Morris, A. A., Prabhu, S. D., Arora, G., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.07.009 · Cited by 5
Modarressi, T. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100706 · Cited by 5
Madan, S., Farooq, M., Diab, K. A., Arfaras-Melainis, A., Palo, K. E. D., Crandall, J. P., Rodríguez, C. J., & Jorde, U. P. (2021) · Endocrine · doi:10.1007/s12020-021-02929-1 · Cited by 4
Optimizing Diabetes Care Through Listening to Multiple Voices
Caballero, A. E. (2024) · Diabetes Spectrum · doi:10.2337/ds24-0015 · Cited by 1
Research works printed but not linked: 3
- National Institutes of Health, 2024, Minority Health and Health Disparities Strategic Plan 2021–2025
- Healthy People 2030, 2024, Priority Areas: Social Determinants of Health
- Healthy People 2030, 2024, Building a Healthier Future for All
Cited by
Vafeidou, K., Psoma, O., Apostolidis, E., Sarvani, A., Doumas, M. N., Kotsa, K., Tsimihodimos, V., & Koufakis, T. (2025) · Geriatrics · doi:10.3390/geriatrics10060144 · Cited by 8
“Reports often highlight higher uptake in academic or specialized centers compared to community practices [24].”
Obi, M. F., Ahmad, S., & Ezechukwu, K. (2026) · Cureus · doi:10.7759/cureus.106266 · Cited by 1
“Notably, race and ethnicity explained about 26% of the variation, highlighting the ongoing impact of structural and financial inequities [27].”
InfluentialYoung, C. F., O’Brien, K., Neumiller, J. J., Isaacs, D. M., Shubrook, J. H., & Clements, J. N. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc25-0049
Avenatti, E., Sadhu, A., Gullapelli, R., Rao, A., Pavuluri, C., Nasir, K., & Kashyap, S. R. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101733
“Policy reforms — such as price negotiations, generic options, and value-based formularies — are essential to promote equitable access [14].”
Self-citationTreleaven, L., Hong, A., Kiburg, K., Cording, A., O'Neal, D. N., & MacIsaac, R. J. (2026) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.70088
“20 This study has several limitations.”
Metadata
- Authors
- Jack, G. A., Avenatti, E., Kashyap, S. R., & Sadhu, A. R.
- Affiliations
- Weill Cornell Medicine (US)
- Houston Methodist (US)
- Corresponding author
- Sadhu, Archana R
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2025-05-27
- Volume
- 110
- Issue
- 9
- Pages
- e2852-e2863
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC12342368
- OpenAlex
- W4410789150
- Cited by
- 9
- References
- 81
- Citations by year
- 2026: 8 · 2025: 1
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Weill Cornell Medicine
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- SGLT2 inhibitors, type 2 diabetes, health disparities, cardiorenal protection, chronic kidney disease, heart failure, atherosclerotic cardiovascular disease, underrepresentation in clinical trials, women, racial minorities, socioeconomic status, prescribing patterns, guideline adherence
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Healthcare Disparities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.